Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J2P-MC-LXBD Phase 2 Study of LY3556050 in Diabetic Peripheral Neuropathic Pain
2023-506127-29-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing LY3556050 arm with Placebo arm (2 arms). Primary endpoint: Mean change from baseline in average pain intensity. Planned start Feb 2024; status: authorised.
02
Drugs
ly3556050
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2023-506127-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506127-29-00.